ArticleBiochemical and biophysical research communications2026
Molecular mechanisms of protein disulfide isomerase antagonism by punicalagin.
Article in Biochemical and biophysical research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Punicalagin, an ellagic acid polyphenol from pomegranate, has been proposed as an antagonist of protein disulfide isomerase (PDI) and endoplasmic reticulum resident protein 57 (ERp57)-thiol isomerases that regulate protein folding and extracellular thrombotic signaling. Here, biochemical oxidase and reductase assays on PDI showed that punicalagin inhibits both activities with micromolar potency, thereby extending earlier work that described disulfide reductase inhibition. Using purified domains to determine potential interaction sites indicated that punicalagin antagonizes both the N-terminal a and C-terminal a' domains similarly. Broader profiling of the PDI family demonstrated that punicalagin selectively inhibits the oxidase activity of multiple thiol isomerases while leaving ERp72 unaffected. In parallel, jump-dilution experiments revealed a reversible mechanism of inhibition. Thiol labeling of PDI's catalytic cysteines detected no change in the redox state, supporting a noncovalent, allosteric mechanism. Complementary spectrophotometric and fluorometric assays showed that punicalagin coordinates with zinc to further inhibit PDI, suggesting metal complexation as an additional feature that may shape its interaction with thiol isomerases. Extensive molecular docking and molecular dynamics simulations showed that punicalagin binds stably and preferentially to defined sites on both the N- and C-terminal domains through extensive hydrogen bonding and van der Waals contacts. Finally, artificial intelligence-driven network analysis identified PDI as a high-confidence target of punicalagin and related galloylated polyphenols, alongside additional signaling proteins. Together, these findings provide further mechanistic framework for punicalagin-mediated antagonism of PDI and highlight galloylated polyphenols as promising scaffolds for PDI-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.